Fig. 1. Study design. *Screening period of up to 5 weeks. At the discretion of the medical monitor, participants could be rescreened once, and an extra 15 screening days were allowed for repeat endometrial biopsy if needed.

Neal-Perry. Fifty-Two–Week Fezolinetant Safety. Obstet Gynecol 2023.